28 results about "Prevotella" patented technology

The invention belongs to the technical field of biology, and discloses a polypeptide derived from a deep sea ecological environment, an application of the polypeptide in preparation of an antibacterial preparation and an antibacterial drug. According to the application of the polypeptide disclosed by the invention in the preparation of the antibacterial preparation, the polypeptide comprises one or more of amino acid fragments with sequences shown as SEQ ID NO: 1-9, the compound has good bacteriostatic or bactericidal activity on one or more of escherichia coli, halomonas aeruginosa, acinetobacter picoteri, staphylococcus aureus, linear preristeria, klebsiella pneumoniae and vibrio parahaemolyticus, and has extremely low toxicity on mammalian cells under an effective concentration. The compound has excellent bacteriostatic activity, bacteriostatic broad-spectrum property and biocompatibility, and has very excellent application prospects in multiple fields such as food preservation, agricultural disease prevention and control, feed additives and the like.

This invention belongs to the field of pharmaceutical technology, and relates to the use of a combination of sour cherry powder and celery seed powder, and complexes containing this composition. Specifically, the sour cherry powder and celery seed powder composition is used in the preparation of drugs for treating or regulating intestinal flora imbalance caused by hyperuricemia. The preparation method of this composition is as follows: pitting sour cherries, freezing them separately with liquid nitrogen, grinding them into powder using a pulverizer, and sieving them separately to obtain sour cherry powder and celery seed powder; mixing the obtained sour cherry powder and celery seed powder at a ratio of (0.5~3):1. This invention discusses the diversity, richness, and evenness of intestinal flora through diversity analysis, community bar chart analysis, and Venn diagram analysis. The results show that this composition can increase beneficial bacteria (Prevotella, Mulliez, Lactobacillus, etc.), reduce harmful bacteria (Alternaria), improve the structure of intestinal flora, and maintain the balance of intestinal flora.

The application discloses a kind of adolescent autism intestinal microorganism marker and application thereof, belong to the field of biological medicine.The microorganism marker includes one or more of Ruminococcus gnavus, Streptococcus thermophilus, Streptococcus salivarius, Butte's intestinal bacillus, pet big anaerobic clavulanic acid bacteria and Prevotella pittmanniae.The application provides a kind of product (such as kit), including detection reagent for detecting the relative abundance of the microorganism marker.The product provided by the application has good feasibility and accuracy, and can effectively evaluate whether adolescent has the risk of autism, provides a new tool for clinical diagnosis.

This invention relates to the field of gene detection technology, specifically to a primer set and its application, and a training method for a bacterial vaginosis diagnostic model. The primer set, used for diagnosing bacterial vaginosis, includes specific primers for specifically amplifying target regions of the following pathogens: *Atopobacterium vaginalis*, *Gardnerella vaginalis*, *Cyclophorus 1*, *Cyclophorus 2*, *Bacterial Vaginosis-Associated Bacteria 2*, *Animal Curvularia clarithii*, *Animal Curvularia emblica*, *Prevotella 2*, *Lactobacillus curvularia*, *Lactobacillus indolentus*, *Lactobacillus gasseri*, and *Lactobacillus janniae*. This invention also provides the application of this primer set and a training method for a bacterial vaginosis diagnostic model. Using this primer set, high-throughput sequencing can be performed on test samples, simultaneously detecting 12 target pathogens, and further constructing a bacterial vaginosis diagnostic model, which can be used for the clinical diagnosis of bacterial vaginosis with good specificity and sensitivity.

The invention discloses a kit for detecting intestinal core bacteria by a TaqMan real-time fluorescent quantitative PCR (Polymerase Chain Reaction) method, and belongs to the technical field of kits. The kit disclosed by the invention comprises standard positive templates of nine common intestinal core bacteria and nine groups of specific primers and probes which are required in a PCR amplification process and correspond to the standard positive templates. The kit disclosed by the invention is simple, convenient and rapid to operate; the specificity is good and the sensitivity is high; complicated raw information data analysis does not need to be carried out; the intestinal core bacteria can be detected and quantified without high-throughput sequencing, and three bacteria can be detected in one reaction hole, so that the cost is greatly reduced. The kit provided by the invention can be used for rapidly and quantitatively detecting nine intestinal core bacteria including bifidobacterium, lactobacillus, prevotella, bacteroides and the like, can partially replace a high-throughput detection method which is higher in cost and more complicated to operate according to research and diagnosis purposes, and is suitable for being widely popularized in clinical detection and laboratory research.

The invention relates to the technical field of medicine, and particularly discloses a liver cirrhosis specific intestinal flora marker composition and application of the liver cirrhosis specific intestinal flora marker composition in noninvasive diagnosis. The intestinal microbial flora is selected from the group consisting of clostridium, Bacteroides, Thalictrum, Wehonor genus, Streptococcus genus, Klebsiella genus, and Prevotella genus; according to the method, a non-invasive solution is provided for screening and diagnosis of liver cirrhosis by detecting a synergistic change mode of specific florae such as clostridium, bacteroides, thickenella, prevotella, Wehonor, streptococcus and klebsiella in an excrement sample; the limitation that traditional liver needle biopsy is invasive and imaging examination is insensitive to early-stage lesions is avoided.

The invention discloses an intestinal flora marker related to metabolic heterogeneity of azathiopurine (AZA) and application of the intestinal flora marker, and belongs to the technical field of personalized drug treatment of inflammatory bowel diseases (IBD). In particular, the invention finds that a specific intestinal flora marker is significantly related to the level of an AZA active metabolite 6-thiopurine nucleotide (6-TGN). For example, the prevotella abundance can be used for distinguishing IBD patients with different 6-TGN exposure levels, has an indication effect on the in-vivo 6-TGN concentration, and has an important application value in thiazopurine therapeutic drug monitoring (TDM). In addition, clostridium species Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are significantly enriched in a 6-TGN high-exposure patient group, and the microbiome of the clostridium sp.OF09-36 and Clostridium sp.AF32-12BH encodes enzyme genes participating in purine metabolism, such as GMPS, HPRT, IMPDH and the like, which indicate that the Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are potential intestinal flora targets for regulating and controlling AZA metabolism. The intestinal flora marker provided by the invention provides a new biomarker and an intervention target for optimization and adjustment of AZA therapeutic dose and individualized precise treatment of IBD.

This invention belongs to the fields of bioinformatics and medical testing technology, specifically relating to a combination of biomarkers related to the postoperative prognosis of colorectal cancer and their application and prediction system. This invention, through 16S rRNA gene sequencing of tumor mucosal samples from colorectal cancer patients, combined with long-term postoperative follow-up data and screening, found that *Peptostreptococcus*, *Fusobacterium*, *Bacteroides*, *Porphyromonas*, and *Prevotella* are closely related to postoperative recurrence of colorectal cancer, with an AUC of 0.81 for assessing postoperative recurrence. Based on this, this invention conducts non-targeted metabolomics analysis, finding that combining alanine glutamate, putrescine, arginine, histidine, and sebacic acid with the above microbial biomarkers can improve the AUC to 0.91, significantly enhancing accuracy, specificity, and precision. This enables prognostic stratification of recurrence-free survival in colorectal cancer patients, demonstrating higher predictive efficacy and stability.

The application belongs to the technical field of biological detection, and particularly relates to a biomarker for idiopathic hyperaldosteronism and application thereof. The biomarker for idiopathic hyperaldosteronism is human intestinal microorganisms, and the human intestinal microorganisms include one or more combinations of Desulfovibrionales, Peptostreptococcaceae, Ruminococcus or Prevotellaceae. A diagnostic model constructed based on the biomarker (two or more of Desulfovibrionales, Peptostreptococcus, Ruminococcus or Prevotella) provided by the application can be used for auxiliary diagnosis of idiopathic hyperaldosteronism, and has high accuracy, excellent sensitivity and good specificity.

The invention discloses a preparation method of a ficus microcarpa extract and application of the ficus microcarpa extract in intestinal flora disorder caused by circadian rhythm disorder. Pharmacological experiments prove that the ficus striata flavone has a remarkable regulating effect in a circadian rhythm disorder injury model: the ficus striata flavone can be used for effectively solving the problems that the diversity of intestinal flora is reduced, the excessive propagation of firmictures, the expression of Bacteroidetes is reduced and the like, which are caused by circadian rhythm disorder, and can be used for preventing and treating the diseases caused by circadian rhythm disorder, so that the ficus striata flavone can be used for preventing and treating the diseases caused by circadian rhythm disorder. Meanwhile, circadian rhythm oscillation of key bacteria such as prevotella, Bacteroides and Clostridium can be adjusted, and increase of the F / B ratio is reduced, so that the rhythm and stability of intestinal flora are improved. The invention simultaneously discloses two preparation processes, namely an ethanol reflux-resin purification method and a water extraction-concentration-alcohol precipitation method, so that the stable quality of the extract is ensured, and the industrial feasibility is realized.

The invention relates to a hyperglycemia individual alpha-linolenic acid accurate intervention system based on intestinal flora types, and belongs to the technical field of accurate nutrition and metabolic disease intervention. The flora typing module is used for determining that the intestinal flora type is bacteroid or prevotella; the alpha-linolenic acid supplementing module is used for determining an alpha-linolenic acid supplementing scheme according to the flora typing result; if the intestinal flora type is bacteroid, regulating blood sugar by supplementing alpha-linolenic acid; if the intestinal flora type is a prevotella type, the blood sugar is not regulated by supplementing the alpha-linolenic acid. According to the method, intestinal flora typing is used as a predictive factor of the ALA intervention effect for the first time, and the problems of non-uniform response rate and indefinite effect caused by neglecting individual flora heterogeneity in the prior art are solved.

Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and / or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Flavonifractor, Dielma, Akkermansia, Alistipes, Bacteroides, Butyricimonas, Vampirovibrio, Tyzzerella, Parabacteroides distasonis, Fournierella, Fournierella massiliensis, Eisenbergiella tayi, Tissierellales, Hungateiclostridium thermocellum, Dorea formicigenerans, Caloramator coolhaasi, Muricomes, Geosporobacter, Prevotella paludivivens, Lactobacillus secaliphilus, Bacteroides finegoldii, Lactobacillus johnsonii, Parapedobacter composti, and Anaerotignum lactatifermentans and wherein the method further comprises treating the subject with a combination of (i) a PD-1, PDL1, or PDL2 inhibitor and (ii) a CTLA-4, B7-1, CN or B7-2 inhibitor.

This invention relates to a novel strain of Prevotella merde immunoactis and its uses. The inventors have confirmed that the novel strain of Prevotella merde immunoactis (deposit number: KCTC 14922BP) not only increases T cell proliferation, increases T cell IFN-γ secretion, increases the expression or activity level of IFN-γ or Cxcl9, and decreases the expression or activity level of Ccl22, but also enhances the anticancer effect of immune checkpoint inhibitors. Therefore, the novel strain of Prevotella merde immunoactis or its culture medium is expected to be useful for immune enhancement and enhancing the anticancer effect of immune checkpoint inhibitors.

The invention belongs to the technical field of biomedical detection, and particularly relates to a model for predicting responsiveness of glucocorticoid to SLE (systemic lupus erythematosus) treatment and application of the model, the model comprises syntrophs, prevotella, parabacteroides diels and Megamonas, through the model, the responsiveness of the glucocorticoid to the systemic lupus erythematosus treatment can be accurately predicted, and the application of the model to the SLE treatment is promoted. The short-term curative effect of the systemic lupus erythematosus patient on the glucocorticoid is predicted, the treatment scheme is optimized, and support is provided for individualized treatment decision in clinical medicine.

The invention discloses an application of a bacterial strain in production of an external product for improving the micro-ecology of the vagina of a human body, and the bacterial strain is Lactobacillus crispatus SPR003 and has 16S rDNA (ribosomal deoxyribonucleic acid) as shown in SEQ ID NO.1. The invention further discloses a preparation method of the bacterial strain for improving the micro-ecology of the vagina of the human body. The preservation number is GDMCC NO: 66664; the strain produces H2O2 and only produces D-lactic acid, and no drug-resistant gene is found; the external product is suitable for improving changes, caused by vaginal pathogenic bacteria, of micro-ecology of the vagina of the human body. Compared with other lactobacillus crispatus of the same type, the strain has the advantages that the H2O2 production capacity is high, the H2O2 production speed is high, the total amount of H2O2 produced within 12 hours is large, and the concentration of hydrogen peroxide can reach about 220 mu M / L after the strain is cultured for 12 hours in the conventional inoculation amount of 1%. H2O2 is a strong oxidant, and can directly kill or inhibit a plurality of pathogenic bacteria and conditioned pathogenic bacteria such as Gardner bacteria, campylobacter actinomycetes, prevotella and other BV-related anaerobic bacteria.

This invention belongs to the field of biomedical and analytical technology and provides an early screening model for esophageal cancer based on oral microorganisms and a method for constructing the same. [Solution] The early screening model uses the oral microbiome, including Prevotella, Granulicatella, Rothia, Prevotellamassilia, Blautia, Abiotrophia, Peptostreptococcus, Actinomyces, Burkholderia, Akkermansia, Fudania, Kineothrix, Bacillus, Duncanella, and Eisenbergiella, as markers. By identifying non-invasive biomarkers, asymptomatic esophageal cancer patients can be detected early.

Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with altered and improved target specificity and their use in genomic engineering, epigenomic engineering, genome targeting, genome editing, and in vitro diagnostics.

This invention discloses the application of the compound pimozide in combination with metronidazole in the preparation of a drug for improving oocyte quality and treating endometriosis-related fertility disorders, belonging to the field of biomedical technology. The efficacy of this invention was verified by constructing mouse models of endometriosis driven by pathogenic *Prevotella bisporus* and mouse models of ovarian endometriosis. Experimental results showed that the combined administration significantly eliminated *Prevotella bisporus* colonizing ectopic lesions, reduced succinic acid content in both eutopic and ectopic lesions, decreased the succinylation level of lysine residue 195 of the ACADVL protein, reduced the fluidity of primary endometrial epithelial cell membranes, reduced the volume and weight of endometriotic lesions, and improved oocyte spermatogenesis, ovulation rate, and litter size. This invention solves the problem that existing therapies cannot simultaneously control endometriosis lesions and protect reproductive function, providing a new, safe, and effective combined treatment option for patients with endometriosis and infertility.

Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with altered and improved target specificity and their use in genomic engineering, epigenomic engineering, genome targeting, genome editing, and in vitro diagnostics.

The application discloses application of Qijiao Shengbai capsules in preparation of medicines for regulating intestinal microorganism flora disorder. The Qijiao Shengbai capsule is composed of Xue Renshen, Huangqi, Ajiao, Danggui, Da Zao, Ku Shen and Yinyanghe. By using the Qijiao Shengbai capsule, the microorganism flora is increased in the level of Firmicutes, increased in the level of Proteobacteria, reduced in the level of Bacteroidetes, reduced in the level of Akkermansia muciphila, and reduced in the level of Actinobacteria; in the level of genus, the microorganism flora is increased in the level of Prevotella, increased in the level of Lactobacillus, increased in the level of Parabacteroides, reduced in the level of Bacteroides, reduced in the level of Enterobacter, and reduced in the level of Staphylococcus, so as to regulate the intestinal microorganism flora. The application provides a new idea for research and development of medicines for preventing and treating intestinal flora disorder.

Provided herein are therapeutic agents, e.g., T, such as atopic dermatitis and / or food allergies. H Compositions and methods relating to Prevotella bacteria that may be useful as therapeutic agents for the treatment of HIV-2 mediated conditions.

This invention belongs to the field of biotechnology, specifically relating to an antimicrobial peptide for improving intestinal health and combating diarrhea in animals, and its preparation method. The invention prepares a novel antimicrobial peptide with the amino acid sequence shown in SEQ ID NO:1. Experiments have verified that after one week of feeding in an unfamiliar environment, the antimicrobial peptide can slightly increase the levels of propionic acid and butyric acid in the experimental group of cats. Furthermore, the overall BCFAs levels in the experimental group were lower than those in the control group before and after transportation. Although there were no significant differences in α-diversity and β-diversity between the experimental group fed the antimicrobial peptide and the control group, feeding the antimicrobial peptide significantly increased the levels of Bacteroides, Parabacterium, and Prevotella in the experimental group, and significantly reduced the levels of harmful bacteria Salmonella and Actinomyces. Therefore, the antimicrobial peptide of this invention can be used to prepare products for improving intestinal health and combating diarrhea in animals, such as feed additives or oral liquids.

The application discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the technical field of liquid biopsy and microbiome. The cervical cancer plasma circulating microbial marker combination comprises Prevotella, Sneathia, Chlamydia trachomatis, Peptostreptococcus, Fusobacterium, Campylobacter and Haemophilus. The cervical cancer plasma circulating microbial marker combination is used for verifying cervical cancer patients and healthy people, and the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, which indicates that the cervical cancer plasma circulating microbial marker combination can effectively distinguish cervical cancer patients from healthy people, is suitable for early screening of cervical cancer, and has significant clinical screening application value.

This invention discloses a type of endophytic fungus, *Priscilla megaterium*, with antibacterial activity, and its applications. The *Priscilla megaterium* is named... Priestia megaterium The strain, g-2-2, has the accession number CGMCC No. 37094. This invention screened and isolated a strain of *Priscilla gigantea* with antibacterial activity, g-2-2. Identification using morphology and 16S rRNA biotags confirmed g-2-2 as *Priscilla gigantea*. This strain exhibits significant inhibitory activity against harmful *Verticillium* species and can be used as a biocontrol agent.

The invention belongs to the technical field of biological medicine and analysis, and provides an esophageal cancer early screening model based on oral microorganisms combined with oral health related behavior variables and a construction method thereof. The model is the following oral cavity microbial flora and oral cavity health related behavior variables: Prevotella, Granulicalala, Rothia, Prevotella, Blauria, Abiotrophia, Peptostreptococcus, Actinomyces, Burkholderia, Akkermansia, Fudania, Kineothrix, Bacillus, Duncaniella, Eisenbergiella, and a tooth brushing frequency, and the oral cavity health related behavior variables are selected from the group consisting of the following oral cavity microbial flora and oral cavity health related behavior variables. By identifying non-invasive biomarkers in combination with oral health related behavior variables, esophageal cancer patients without symptoms in the early stage can be found.

The application discloses application of Prevotella in prevention and treatment of attention deficit hyperactivity disorder, and the Prevotella is used for treating attention deficit hyperactivity disorder, and the Prevotella is used in a therapeutically effective amount to achieve treatment of attention deficit hyperactivity disorder, and the strain number of the Prevotella is JCM 13464=DSM 18205. Through animal experiment verification, the Prevotella can significantly improve hyperactivity behavior, spontaneous activity level and impulsive behavior; and through further exploration in experiments, it is found that the Prevotella can significantly increase the levels of adrenocorticotropic hormone and cortisol in serum, improve the dysfunction of the neuroendocrine system, significantly increase the gene expressions of glucocorticoid receptors (Nr3c1) and mineralocorticoid receptors (Nr3c2), and then relieve social dysfunction of ADHD, so that a theoretical basis is provided for application prospects of probiotics in relieving ADHD.

This invention discloses a metabolomics-gut microbiome biomarker combination for the diagnosis of HIV-related asymptomatic neurocognitive impairment (ANI), comprising metabolomics biomarkers and gut microbiome biomarkers. The metabolomics biomarkers include plasma and fecal biomarkers. Plasma biomarkers include Asp-Asn and arachidonic acid, while fecal biomarkers include histidine, lysine, ornithine, and indolelactone. The gut microbiome biomarkers include phylum-level and genus-level biomarkers. Phylum-level biomarkers include Firmicutes, Actinobacteria, and Proteobacteria, while genus-level biomarkers include *Clostridium*, *Microbacterium*, *Klebsiella*, and *Prevotella*. This biomarker combination integrates the core differential features of metabolomics and gut microbiota, exhibiting high diagnostic specificity and sensitivity. It can effectively distinguish ANI patients from CI patients and healthy individuals, providing a clear target for HAND targeted intervention and possessing significant clinical application value.

Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and / or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Flavonifractor, Dielma, Akkermansia, Alistipes, Bacteroides, Butyricimonas, Vampirovibrio, Tyzzerella, Parabacteroides distasonis, Fournierella, Fournierella massiliensis, Eisenbergiella tayi, Tissierellales, Hungateiclostridium thermocellum, Dorea formicigenerans, Caloramator coolhaasi, Muricomes, Geosporobacter, Prevotella paludivivens, Lactobacillus secaliphilus, Bacteroides finegoldii, Lactobacillus johnsonii, Parapedobacter composti, and Anaerotignum lactatifermentans and wherein the method further comprises treating the subject with a combination of (i) a PD-1, PDL1, or PDL2 inhibitor and (ii) a CTLA-4, B7-1, or B7-2 inhibitor.